Deborah Scott - Vascular Biogenics Managing Communications
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Insider
Deborah Scott is Managing Communications of Vascular Biogenics
| Phone | 972 8 993 5000 |
| Web | https://www.vblrx.com |
Vascular Biogenics Management Efficiency
The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.Vascular Biogenics currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vascular Biogenics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Klaus Orlinger | Hookipa Pharma | 47 | |
| James JD | Allarity Therapeutics | 55 | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Christine MBA | Hookipa Pharma | 59 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Mary DiBiase | X4 Pharmaceuticals | 64 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| MSc MBA | Inozyme Pharma | 53 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Alexandra MD | Avenue Therapeutics | 58 | |
| Karen Cashmere | ZyVersa Therapeutics | 73 | |
| Prof MD | Hookipa Pharma | 81 | |
| MS MBA | Inozyme Pharma | 48 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
Management Performance
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 |
Vascular Biogenics Leadership Team
Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Backenroth, Chief Officer | ||
| Naamit Sher, VP of Devel. and Regulatory | ||
| Yael Cohen, Vice President - Clinical Development | ||
| Erez MBA, Sr Operations | ||
| Eyal Breitbart, Vice President Research | ||
| Deborah Scott, Managing Communications | ||
| Pr MD, CEO Director | ||
| Advocate Horn, G Counsel | ||
| Tami MD, VP Devel |
Vascular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |